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Introduction 35
mice (n=10) 24 hours after s.c. inoculation with 10 4 pfu of WEEV Montana-64, or immediately after s.c. 121 inoculation with 10 4 PFU of WEEV McMillan, a highly neurovirulent strain in mice (27) . 122 For vaccination studies, a recombinant HIS-tagged version of WEEV E1ecto was produced in the 123 baculovirus-insect cell expression system and purified by immobilized metal affinity chromatography, as 124 previously described (24, 28) . Purified E1ecto was added to formed CLNC complexes at a final 125 concentration of 50 µg/mL (10 µg/200 µL dose) unless otherwise noted (as during initial dosage 126 evaluation studies). The antigen was allowed to associate with liposome complexes for 15 minutes with 127 mixing by inversion and the resulting liposome-antigen-nucleic-acid-complexes (LANACs) were used to 128 vaccinate mice (n=10). Each dose of vaccine consisted of 200µL of LANAC delivered via s.c. injection 129 dorsal to the cervical spine. The priming dose was followed by a boost two weeks later. The immunized 130 mice were challenged at 2, 3, 7, 9, or 11 weeks after the booster dose by i.n. or s. In vivo imaging and quantification of luciferase activity. Mice were vaccinated with E1ecto-or sham-137
LANACs using the prime-boost strategy described above. Two weeks after the booster, animals were 138 challenged by i.n. infection with 10 4 pfu of WEEV.McM.FLUC and imaged at 24 and 48 HPI using IVIS 139 200, as previously described (24). Luciferase activity for each acquired image was quantified using 140
Living Image 3.0 software (Caliper Life Science, CA, USA). 141
Virus titration of mouse brain tissue. Whole brains from each treatment group were collected at 72 HPI 142 (n=4) from mice used for the imaging studies, as previously described (24). Samples were removed after 143 a 5 min PBS perfusion by cardiac puncture to ensure all systemic blood was removed. Brains were placed 144 on October 20, 2017 by guest http://jvi.asm.org/ Downloaded from in pre-weighed 1 ml green bead tubes (Roche, Switzerland) containing 0.5 ml MEM and processed, as 145 previously described (13) . 146
Plaque reduction neutralization titer. BHK-21 cells (ATCC) were maintained in MEM supplemented 147 with 10% heat-inactivated fetal bovine serum, 1% glutamine and 100 U/mL of penicillin-streptomycin 148 and used to seed 24-well plates. Plaque reduction neutralization titers (PRNTs) were measured by 149 incubating virus samples with serial dilutions of serum, inoculating samples into each well, and 150
incubating the plates at 37°C in 5% CO 2 for 1 hour. The inocula were aspirated and the cells were 151 overlaid with nutrient agar. After being incubated at 37°C in 5% CO 2 for 3 days, plaques were visualized 152 using3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium Bromide (MTT). Positive controls 153 consisting of virus that was not pretreated with serum were including in each assay. Sera assayed in these 154
PRNTs included sera collected 3 weeks after the booster dose from mice immunized with E1ecto 155
LANACs, negative control serum, and positive control serum from mice that had survived footpad 156 infection with WEEV.McM.FLUC. PRNT endpoints were calculated using probit analysis, as previously 157 described (29). A 50% plaque reduction (PRNT 50 ) was used as the neutralizing end point and the PRNT 50 158 titer was expressed as the reciprocal of the lowest dilution of test sera able to neutralize 50% of the input 159
virus. 160
Mouse serum antibody profile assay. For isotype ELISA, polyvinylchloride plates were coated 161 overnight at 4° C with 100 µl of E1ecto antigen diluted to 2 µg/ml in PBS (pH 7). Plates were washed 162 twice with PBS containing 0.25% TWEEN-20 (PBS-TW) and twice more with PBS. Plates were blocked 163 with 200 µl of SuperBlock T20 (Thermo Scientific) for 1 hour at room temperature then washed as 164 described above. Serum samples were diluted 1:100 in PBS and log2 serial dilutions were added to the 165 plates, followed by 1 hour incubation at room temperature. Isotype-specific detection was performed by 1 166 hour incubation with monoclonal antibodies to IgG1 (clone X56, HRP conjugate), IgG2a (R19-15, HRP), 167
IgG2b (R12-3, biotinylated conjugate), IgG3 (R40-82, biotinylated), IgM (11/41, HRP) Statistical analyses. All titration data were log 10 -transformed and compared using unpaired Student's t 197 test. Analysis was conducted using statistical analysis software (SAS) version 9.2. Survival curves were 198 subjected to Kaplan-Meier (log rank test) analysis using Prism version 6.00 for Windows (GraphPad) . 199 Quantitative analysis of bioluminescence in the assessment of vaccine efficacy was conducted using two-200 tailed t-test. E1ecto provided 100% protection against challenge with WEEV Montana-64 at two weeks after the 222 booster (Fig. 2D) . 223
Next, we determined the protective efficacy of LANACs containing the optimal 10 µg of E1ecto 224 against the more virulent WEEV McMillan strain. The effects of infection route and longevity of the 225 immune response to the E1ecto-LANACs were examined by challenging immunized mice by the s.c. or 226 i.n. routes at two different times after the booster. Immunization with the E1ecto-LANACs provided 227 100% protection against s.c. infection and 60% protection against i.n. infection at two weeks (Fig. 3A ) 228 and 100% protection against virus administered by either route at 11 weeks (Fig. 3B ) after the booster 229
dose. 230
Finally, we examined the protective efficacy of LANACs in mice challenged with WEEV via 231 exposure to infected Culex tarsalis mosquitoes. The results showed that the E1ecto LANACs provided 232 complete protection (Fig. 4A) . Plaque assays confirmed that the viral titers of blood-engorged mosquitoes 233 for infecting E1ecto LANAC-or sham-LANAC immunized mice were not significantly different (Fig.  234 
4B). 235
Bioluminescence imaging for visualizing effects of LANACs on virus replication. We also used 236 imaging to examine non-or E1ecto LANACs-immunized mice 2 weeks after the booster dose with an i.n. 237 inoculation of WEEV.McM.FLUC. The results revealed a significant reduction in the bioluminescence 238 signal observed in the E1ecto LANACs-immunized animals, as compared to non-immunized controls at 239 both 24 and 48 HPI ( Fig. 5A and 5B). In fact, there was no statistical difference in the levels of 240 bioluminescence observed in the immunized animals and uninfected controls ( infectivity in homogenates of brains removed from euthanized animals at 72 HPI at (Fig. 5C ). The 243 immunized mouse brain homogenates produced no plaques, indicating a viral titer lower than the 244 detection limit of our plaque assay (6.6 PFU/mL). In contrast, we observed titers of ~10 7 -10 8 PFU/g tissue 245 in the non-immunized mouse brain homogenates, which was consistent with our previous results (24). 246
Neutralizing and antiviral activities of serum from LANACs immunized mice. The viral 247 neutralization titers of sera from E1ecto LANACs-immunized, non-immunized (normal), and untreated 248 mice that had survived experimental s.c. challenge with recombinant McMillan (survivor) were measured 249 using standard PRNT assays. Like the normal sera, the LANACs-immunized mouse sera had no 250 neutralizing activity (PRNT 50 of <40), while the survivor sera had a PRNT 50 of 200 (Fig. 6A) . We 251 extended these results by imaging Vero cells 24 hr after being infected with WEEV.McM.FLUC and 252 treated (1 HPI) with a 1:200 dilution of sera. The results of this assay showed that sera from the 253 LANACs-immunized mice significantly reduced the bioluminescence signal, as compared to the negative 254 control serum (Fig. 6B and C) . The LANACs-immunized mouse sera also significantly reduced the 255 amount of infectious virus produced by the infected Vero cells (Fig. 6D) , as compared to normal sera. 256 Therefore, although the E1ecto LANACs-immunized mouse sera had no detectable virus neutralizing 257 activity, the sera nevertheless had significant antiviral activity. 258 259 Antibody profiling. To further characterize antigen-specific humoral responses induced by 260 immunization, sera collected at 2 weeks following the first (prime) and second (prime-boost) doses of 261 LANACs or bovine serum albumin (BSA) were was assayed for relative isotype abundance by ELISAs 262 ( Figure 7A ). Sera from naïve, unvaccinated animals were used as controls. The results showed that 263 animals that were prime or prime-boosted with LANACs produced E1ecto-specific IgG, whereas 264 unimmunized and BSA-immunized animals did not. In addition, primed animals produced primarily 265
IgG1, whereas prime-boosted animals produced IgG2a and IgG2b indicating strong class switching. and IgG2b LANACs-immunized (prime boost) mouse sera were >10,000 (Fig. 7B) . There was more 268 animal to animal variability in the IgG2a titers, with 4/10 animals failing to produce a GMT >250. 269
270
Passive transfer of antibodies to confer protection against WEEV. Mice were immunized with 271 LANAC E1ecto and sera were collected 9 weeks later. Pooled sera from immunized mice had an E1ecto 272 antibody titer of 12,800. Four CD-1 mice/group were i.p. inoculated with either immune or non-immune 273 sera as described earlier infected with recombinant WEEV.McM.FLUC virus by the i.n. route. No 274 bioluminescence was detected in either group 10 min after infection. All mice receiving non-immune sera 275
showed progressively intensifying bioluminescence in the head and had pronounced neurological deficits 276 by 96h post-infection when euthanized. Two of four mice injected with E1ecto LANAC immune sera had 277 limited bioluminescence at 24h post-infection; however, all of four mice showed no observable signs of 278 bioluminescence at 48h, 72 and 168h post infection and no observable neurological deficits. An example 279 of two mice, one treated with immune pooled sera and the other with non-immune sera is shown in Figure  280 8A. The mouse treated with immune sera survived beyond 7 days after infection. Figure 8B shows a 281 quantification of bioluminescence of the four animals in the experimental and control groups. All four 282 mice receiving immune sera were alive at 7 days post infection; all mice receiving non-immune or normal 283 sera were euthanized by day 4 post-infection due to neurological deficits ( Figure 8C ). The passive transfer 284 experiments strongly indicate that antibody is the mechanism of protection. 285
Cross-protection against EEEV. Finally, we examined the ability of WEEV E1ecto LANACs to cross-286 protect mice against EEEV. Mice were prime-boost immunized with either sham-LANACs or E1ecto 287
LANACs and challenged at 9 weeks after the booster dose by s.c. or i.n. inoculation with EEEV (Florida-288 93; Fig. 9A ). Mice immunized with the E1ecto LANACs survived the virus challenge via either route at 289 significantly higher levels (p value = < 0.0001) than the sham-LANAC controls. In fact, 9/10 CD-1 mice 290 from each group immunized with the E1ecto LANACs survived EEEV (Florida-93) challenge, with only 291 on October 20, 2017 by guest http://jvi.asm.org/ Downloaded from one from each group euthanized at 9 days post-challenge due to neurological deficits, while all 10 mice 292 immunized with the sham-LANACs were euthanized at days 6 or 7 due to obvious neurological deficits. 293
In contrast, mice immunized E1ecto LANACs and challenged at 2 weeks after the booster dose failed to 294 show any significant difference in protection compared with the sham-LANAC group ( Figure 9B ). These 295 results show that the LANACs formulation containing the recombinant WEEV E1ecto provided strong 296 cross-protection after 9 weeks against the heterologous alphavirus, EEEV. 297
Discussion 298
We describe a new LANACs formulation that is effective against both WEEV and EEEV, two 299 distinct alphaviruses that cause serious human disease. The CLNC component of the LANACs works 300 therapeutically, most likely through innate immune system stimulation, with induction of antiviral activity 301 occurring even when the CLNCs are administered after infection. In contrast, the recombinant E1ecto 302 antigen component of the LANACs induces a humoral immune response providing specific and long-term 303 protection against alphaviral disease. 304
It is not surprising that the CLNC component of our LANACs worked therapeutically against 305 WEEV; CLDCs can rapidly induce potent antiviral activity across a wide-range of viral infections (13, 306 30, 31). We previously reported that CLDCs (liposome-ODN-complexes) protect against s.c. challenge 307 with WEEV in the CD-1 mouse model when administered 24 hours before infection (13). The findings 308 presented here extend our previous results and indicate that cationic lipososomes-ODN-PIC complexes 309 can be used therapeutically against WEEV when administered within the first day of infection. 310 CLNC/ODN/PIC may result in safety issues due to massive cytokine releases and activation of multiple 311 TLR pathways. This will be a topic of future studies in several animal models including marmosets. 312
Our results indicated that CLNCs containing both PIC and ODN had stronger antiviral effects 313 than CLNCs containing only PIC or only ODN. This additive effect might be due to the stimulation of 314 separate innate immune pathways by these molecules. PIC binds TLR3, which can activate MyD88-315 on October 20, 2017 by guest http://jvi.asm.org/ Downloaded from dependent and independent pathways, whereas ODN binds TLR9, which uses a MyD88-dependent 316 pathway. Furthermore, PIC can activate the cytosolic sensors (MDA-5 and RIG-I) (32, 33) triggering 317
IPS-1-dependent pathways (34). 318
Of particular importance was the cross-protection of the WEEV McMillan E1ecto component of 319
LANACs. We purposefully chose this protein antigen for our LANACs formulation for several reasons. 320
First, although E2 protein is the major neutralizing antigen, E1 is highly-conserved among distinct 321 alphaviral species (9, 10) and antibody to E1 is protective (11). Second, the E1 of WEEV is a recent 322 ancestor of the E1 from a Sindbis-like virus, which has been shown to induce cross-reactive and cross-323 protective antibodies (11, 35) . Given WEEV evolutionary history, WEEV E1ecto may be an efficient 324 antigen for developing cross-protective antibodies among NWA and OWA species. Finally, monoclonal 325
antibodies against E1 (McMillan strain) are alphavirus group reactive (36-38). The insect cell-derived 326
McMillan E1ecto antigen presented to mice in the LANACs context (CLNC/ODN/PIC) may explain why 327 our study differs with a previous study that immunized mice with recombinant bacteria-derived WEEV 328 E1 antigen and reported minimal protection to two WEEV strains (3). Gauchi et al (2010) used a DNA 329 vaccine approach to immunize mice with WEEV E1 and demonstrated protection to challenge with a low 330 virulence WEEV strain but not with a high virulence WEEV strain (6, 7). In both studies, WEEV 331 challenge occurred at 2-3 weeks after boost. Our studies showed that maximal efficiency of cross 332 protection occurred at 9-11 weeks after boost suggesting that cross protection to highly virulent WEEV 333 and EEEV strains requires time to develop. In support of this observation, mice that were prime-boost 334 immunized with LANACs containing WEEV E1 antigen and challenged 2 weeks after boost with EEEV 335 (Florida-93) were poorly protected (Fig. 9) . 336
Although LANACs-E1ecto induced a strong humoral immune response, no 337 detectable neutralizing activity was found in serum from immunized animals. The passive transfer of 338 immune sera showed that antibody was sufficient for protection in mice. How, then, might the 339 antibodies protect against fatal CNS infection? One possibility is that the E1 antibodies bind to the 340 on October 20, 2017 by guest http://jvi.asm.org/ Downloaded from surface of infected cells and prevent disruption of host cell membranes, leading to the restoration of 341 membrane potential, host protein synthesis, and interferon responsiveness (39, 40) . 342 Metcalf et al. (2013) reported that viral antigen-specific antibody-secreting cells (ASC) become 343 enriched within the brain following infection with Sindbis virus (41), and that these Sindbis-specific 344
ASCs are maximally enriched (as a percentage of total ASCs within the brain) at 8-9 weeks after 345 inoculation. Such a timeline corresponds well with our observation that 9 weeks is required after boost 346 before vaccine efficacy is realized in cross-protection experiments. It could be that E1ecto-specific ASCs 347 require 9 weeks in order to attain effective enrichment within the CNS. In the Metcalf study, production 348 of IgG2a and IgG2b occurred, but not IgG1, suggesting a role for Th1/IFNγ-mediated class switching. 349
Protective, non-neutralizing monoclonal antibodies developed to SINV were predominantly IgG2a; the 350 one IgG1 isotype generated was not protective (11). In both of these studies, infectious virus was used 351 and such infections may naturally lead to IgG2a/IgG2b responses. In the LANAC work presented here, 352
we found abundant E1-specific IgG1, but not IgG2a, IgG2b, IgG3 or IgM two weeks after priming. Studies are underway to more precisely determine the mechanism of protection. We are currently 361 investigating the effectiveness of our WEEV E1ecto-LANACs formulation to protect mice against other 362 alphaviruses, including VEEV and Chikungunya virus, and remain optimistic that this approach has 363 potential as a broad-spectrum alphavirus vaccine. Finally, LANAC-E1ecto immunization strategy will 364 require efficacy studies in additional animal models including non-human primates. We would like to thank Dr. Steve Dow (Colorado State University) for providing the liposomes, 367
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